Cardiological Society of India – Rajasthan Branch welcomes to the recorded session on Scientific Program, topic "Case based approach to Heart Failure Management ".
HIGHLIGHTS OF THE WEBINAR
Two sessions
Session 1: Dr Rajeev Gupta
Case based approach to Heart Failure Management-
Topic 1: Slow and steady wins the race – stepwise approach
Case 1:
●History and past symptoms
●ACCF/ AHA and NYHA classification explained in detail
●Example papers to explain prognosis and with respect to EF/HF
●Initial Management of the Patient
●Major concerns and further management
●Stepwise therapies as per guidelines
●Foundational therapy (basic pharmacological therapy) with ACEi/ARB ,beta blockers
and MRA
●Reduction in risk of HF and long-term outcomes
●Trails stating benefit of different drugs
●HFrEF therapy guidelines in AHA/ACC/HFSA focussed on ESE guidelines in stepwise
therapy.
●Management using right drug at right level/step
●Canadian guidelines
●Use of ACE inhibitors and beta blockers reduce mortality
●Add drugs only if patient is still symptomatic even after maximum tolerated dose of
conventional therapy
●Polypharmacy should be avoided
●In case of adverse reaction discontinue drugs
●Use of optimal doses in clinal trails, combination therapy and other studies
●Pharmacological therapy - newer drugs available
●Criteria for PARADIGM-HF
●Trail to study effect of DAPAGLIFLOZIN
●AF trail – digoxin shows positive effects
●Discussion of never line of drugs (SGLT2 and ARNI)
Session 2: Dr J C Mohan
Management approach to a patient with HFrEF –
Topic 2: Hit early Hit Hard (SGLT2i should be used early)
Case 2:
●Past History and symptoms
●Initial treatment given
●Relevant data regarding case
●Prevalence of CKD (corelation with eGFR)
●Renal compartment syndrome, abdominal compartment syndrome, reduced forward output
syndrome and pre-existing KD
●The patient has High mortality, recurrent hospitalisations and poor quality of life with HF
●Maggic score – determine prognosis and mortality
●Risk therapy paradox explained
●Explanation of guideline mandated therapy ( Anti RASS , BB ,MRA,SGLT2-i, devices )
●Failure rate of therapy is 60%
●Impactful therapy with other drugs and other approaches
●Comprehensive therapy vs conventional therapy
●Benefits of adding newer drugs early during therapy
●Benefit of Lisinopril , ACE , ARNI , DAPA HF and SGLT2i early with evidence
●Principles of optimising care in HF
●Best three drug combination in this case Explained
●Recommended dose according to the Asian heart failure registry
●Explanation of use of ARNI in the patient
Session 3: Dr Ashwini Kumar Sharma
Recurrent SFC Thrombosis: PTA Under Peripheral IVUF guidance
Case 3:
●Case presentation
●Explanation of procedures done during the course of hospitalization with graphic
presentation
Conclusion:
●CDT is effective in ALI
●Peripheral IVUS is helpful in evaluating the etiology of TVF and aids to angiography in
subsequent management.
Session 4: Dr Rajeev Sharma
Basic EP study
●Baseline and Tachycardia ECG was explained
●Description of Anatomy
●Description of placement of catheter
●Reading and diagnosing ECG
We wish you a great learning experience and thank our sponsors Astra Zeneca to make this program possible.
